On May 22, 2025 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place from May 30 – June 3, 2025 in Chicago, IL (Press release, Natera, MAY 22, 2025, View Source [SID1234653342]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analyses of thousands of patients, demonstrating Natera’s leadership in circulating tumor DNA (ctDNA) monitoring and molecular residual disease (MRD) assessment.

"The depth and breadth of Natera’s research at ASCO (Free ASCO Whitepaper) is our most significant to date, with multiple impactful datasets in several histologies," said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. "The interim analysis from the DARE trial shows a possible first signal in a randomized setting that treating high-risk breast cancer patients based on Signatera results can impact clearance rates. We also look forward to sharing results on our ultra-sensitive Signatera Genome assay, along with numerous other presentations underscoring our commitment to advance the way cancer is managed."

Highlights include:

DARE Clinical Trial: Oral Presentation
DARE is a prospective, randomized study, launched in 2021, to investigate the utility of Signatera for guiding adjuvant endocrine therapy in 585 women with high-risk, estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. It assesses the novel concept of "treatment on molecular recurrence" (TOMR). Patients who were Signatera-positive and imaging-negative were randomized into two arms: the standard-of-care (SOC) arm with endocrine therapy vs. the escalated arm with fulvestrant+palbociclib (CDK 4/6i). This interim analysis of 507 women and 2,208 plasma samples demonstrates the exceptional clinical performance of Signatera, and the early feasibility of both this treatment escalation approach and the TOMR trial strategy, including:
Strong test sensitivity and NPV: Among patients who remained persistently Signatera-negative during screening (>400 pts), 99% remained recurrence free with a median follow up of 27.4 months.
High randomization rate: Of patients who tested Signatera-positive, 73% were negative on imaging, and 93% were willing to be randomized.
2x higher ctDNA clearance: Patients in Arm A had a 2x higher rate of ctDNA clearance at 3 months vs. Arm B.
Signatera Monitoring in Metastatic Breast Cancer: Oral Presentation
This real-world analysis of over 600 metastatic breast cancer (mBC) patients across all disease subtypes and a wide range of therapeutic regimens (e.g., chemo, ADCs, CDK4/6) shows the utility of metastatic monitoring with Signatera:
Serial ctDNA testing done at an appropriate cadence (6 weeks) can inform treatment response and clinical decisions in metastatic breast cancer.
Signatera ctDNA dynamics were the strongest predictor of treatment benefit in a multivariate analysis, based on measuring time to next treatment (TTNT).
Nearly 75% of patients with favorable dynamics remained on the same treatment for over 4 months, including those receiving antibody drug conjugates (ADCs) where therapy response can be challenging to evaluate on imaging.
Pan-Cancer Performance of Signatera Genome: Poster Presentation
Large-scale presentation of Signatera’s Genome assay, analyzing more than 3,000 samples from over 300 patients across 5 major cancer types.
The study includes analysis of patients with breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma.
Signatera Performance in Post-Surgical Stage I-IIIb Melanoma: Poster Presentation
This study includes 197 patients and 1,681 plasma samples, tested for a median period of 2 years. This is one of the most comprehensive MRD/monitoring datasets thus far in early melanoma, demonstrating the ability of Signatera to identify patients who may benefit from escalated imaging or earlier treatment initiation.
Post-surgical Signatera-positivity was the most significant predictor of recurrence free survival (RFS).
In the surveillance setting, Signatera-positivity was predictive of shorter RFS (HR: 24.0, P < 0.001).
Full list of oral presentations at ASCO (Free ASCO Whitepaper):

May 30, 2:45 PM CT | 3008 | Breast
Presenter: Silver Alkhafaji
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial

June 1, 9:45 AM CT | 4503 | Genitourinary
Presenter: Thomas Powles, MBBS, MRCP, M.D.
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA

June 1, 11:30 AM CT | 3518 | Gastrointestinal
Presenter: Aron Bercz, M.D.
Circulating Tumor DNA Provides an Early Response Assessment in Anal Squamous Cell Carcinoma Treated With Definitive Chemoradiation

June 1, 4:30 PM CT | 1010 | Breast
Presenter: Lajos Pusztai, M.D., DPhil
Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer (BC) during adjuvant endocrine therapy (ET) (DARE)

June 1, 4:30 PM CT | 1011 | Breast
Presenter: Pedram Razavi, M.D., Ph.D.
Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)

June 2, 3:00 PM CT | 504 | Breast
Presenter: Rita Mukhtar, M.D.
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial

Full list of poster presentations at ASCO (Free ASCO Whitepaper):

May 31, 9:00 AM CT | 11537 | Sarcoma
Presenter: Adie Victor, M.D., M.S.
Early on-treatment circulating tumor (ct)DNA dynamics in response to therapy in patients with sarcoma

May 31, 9:00 AM CT | 11531 | Sarcoma
Presenter: Maggie Zhou, M.D.
Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma

May 31, 9:00 AM CT | TPS3647 | Gastrointestinal
Presenter: Clara Montagut, M.D.
A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS Trial.

May 31, 9:00 AM CT | 4067 | Gastrointestinal – FMI
Presenter: Michele Prisciandaro, M.D.
Tumor-informed liquid biopsy in predicting recurrence in patients with operable gastroesophageal adenocarcinoma: the LIQUID study

May 31, 9:00 AM CT | 4130 | Gastrointestinal
Presenter: Maen Abdelrahim, M.D.
Real-world analysis of ctDNA and other biomarkers in patients with curatively resected Stage I-III Biliary Tract Cancer

May 31, 9:00 AM CT | 3600 | Gastrointestinal
Presenter: Eiji Oki, Ph.D.
Impact of Perioperative Complications on ctDNA-based MRD Detection and Prognosis: Insights from the GALAXY Study

May 31, 9:00 AM CT | 3591 | Gastrointestinal
Presenter: Emerik Osterlund, M.D., Ph.D.
Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study

May 31, 9:00 AM CT | 3597 | Colorectal
Presenter: Midhun Malla, M.D., M.S.
ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer

May 31, 9:00 AM CT | 4073 | Esophagogastric Gastric
Presenter: Reetu Mukherji, M.D.
Exome analysis of over 5000 esophagogastric cancers

June 1, 9:00 AM CT | 9574 | Merkel Cell Carcinoma
Presenter: Joshua Elbridge Chan
Comparison of surveillance circulating tumor DNA and merkel polyomavirus antibody titer for detection of merkel cell carcinoma recurrence

June 1, 9:00 AM CT | 9571 | Melanoma
Presenter: George Ansstas, M.D.
Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma

June 1, 9:00 AM CT | 9523 | Melanoma
Presenter: Caroline Burkey
Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study.

June 1, 9:00 AM CT | 9584 | Melanoma
Presenter: Vincent The-Luc Ma
Sensitivity of circulating tumor DNA (ctDNA) for disease recurrence or relapse in melanoma patients

June 1, 9:00 AM CT | 5563 | Gynecological
Presenter: Jung-Yun Lee, M.D., Ph.D.
ctDNA monitoring in participants with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) plus chemotherapy (chemo) with or without the anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830

June 2, 9:00 AM CT | 4565 | Genitourinary
Presenter: Adanma Ayanambakkam, M.D.
Association of Tumor-Informed ctDNA-based Molecular Residual Disease (MRD) with Clinical Outcomes for Upper Tract Urothelial Cancer (UTUC)

June 2, 9:00 AM CT | 4602 | Genitourinary
Presenter: Ilana Epstein
Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT)

June 2, 9:00 AM CT | 4560 | Genitourinary
Presenter: Kevin R. Reyes, BS
Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with Enfortumab Vedotin +/- Pembrolizumab (EVP)

June 2, 9:00 AM CT | TPS620 | Breast
Presenter: Michail Ignatiadis, M.D., Ph.D.
EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)

June 2, 9:00 AM CT | 581 | Breast
Presenter: Julia Foldi, M.D., Ph.D.
Serial circulating tumor DNA (ctDNA) monitoring in early-stage, HR+/HER2-, invasive lobular carcinoma (ILC) of the breast and impact on clinical outcomes

June 2, 9:00 AM CT | 560 | Breast
Presenter: Marla Lipsyc-Sharf, M.D.
Cadence of circulating tumor DNA (ctDNA) testing for molecular surveillance in early-stage breast cancer (eBC)

June 2, 9:00 AM CT | 612 | Breast
Presenter: Mei Wei, M.D.
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC)

June 2, 1:30 PM CT | 3142 | Pancancer
Presenter: Mridula George, M.D.
Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors

June 2, 1:30 PM CT | 3048 | Gastrointestinal
Presenter: John Paul Y.C. Shen, M.D.
Development of a methylation-based, tissue-free test for the detection of molecular residual disease by circulating tumor DNA

About Signatera

Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. The test is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in more than 100 peer-reviewed papers.

On May 22, 2025 Flatiron Health reported 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago (Press release, Flatiron Health, MAY 22, 2025, View Source [SID1234653341]). These studies exemplify Flatiron’s commitment to advancing cancer research and align with this year’s ASCO (Free ASCO Whitepaper) theme, "Driving Knowledge to Action: Building a Better Future," by delivering critical evidence to inform and improve patient care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution," said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. "Our research accepted at this year’s ASCO (Free ASCO Whitepaper) demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer."

Highlights include:

a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer
an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer
an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings
Schedule a meeting with Flatiron Health at ASCO (Free ASCO Whitepaper) 2025, and learn more about our abstracts and events, including workshops and panels.

Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131.

Abstracts and Poster Presentations
Racial and ethnic differences in biomarker testing for targetable alterations among patients with HR+ HER2- metastatic breast cancer (mBC)
Catherine Keane, Gene G. Ho, Samantha Reiss, Melissa Estevez, Katherine Harrison, Anca Marinescu, Olive Mbah
Breast Cancer—Metastatic
Poster board: 63
Abstract number: 1084

Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)
Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. Cohen
Breast Cancer—Local/Regional/Adjuvant
Poster board: 148
Abstract number: 555

Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): insights by PTEN status
Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca
Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li
Genitourinary—Prostate, Testicular, and Penile
Poster board: 295
Abstract number: 5096

Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data
Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz
Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal
Quality Care/Health Services Research
Poster board: 436
Abstract number: 11097

Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer
Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago
Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster board: 199
Abstract number: 8078

Molecular residual disease (MRD) in solid tumors
Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center
Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol
Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster board: 486b
Abstract number: TPS3186

Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen – Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US)
Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals
Online publication only

Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study
Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists
Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia
Online publication only

A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC)
Partner: Incyte
Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu
Online publication only

A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens
Partners: Merck & Co, MSD UK, Mayo Clinic
Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh
Online publication only

Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting
Partners: Cleveland Clinic, Merck KGaA, EMD Serono
Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter
Online publication only

Concordance of response-based clinical trial and machine learning–generated real-world end points
Partner: Genentech
Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee
Online publication only

Real-world progression-free survival of CDK4/6 inhibitors (CDK4/6i) plus an aromatase inhibitor (AI) in HR+/HER2− MBC in US routine clinical practice
Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center
Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky
Online publication only

Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse
Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center
Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour
Online publication only

On May 22, 2025 OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, reported it has entered into a collaboration agreement with Mayo Clinic (Press release, Mayo Clinic, MAY 22, 2025, View Source [SID1234653340]). The agreement provides OncoSwab with access to clinical research expertise and know-how to support the development of its nasal swab-based diagnostic platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration centers on enabling clinical validation of OncoSwab’s lead diagnostic test, which utilizes genomic biomarkers from nasal fluid to detect lung cancer and expanding the technology into additional indications.

"Our goal is to deliver accurate, accessible diagnostics that empower clinicians to detect cancer earlier and with greater ease" said Andrea Stephany Díaz, co-founder and CEO of OncoSwab.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

On May 22, 2025 Caris Life Sciences (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, reported that the company and collaborators within the Caris Precision Oncology Alliance (Caris POA) will collectively present 37 abstracts across 16 tumor types at the upcoming 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, from May 30 – June 3, in Chicago, IL (Press release, Caris Life Sciences, MAY 22, 2025, View Source [SID1234653339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s ASCO (Free ASCO Whitepaper) abstracts highlight the growing clinical value of integrated molecular profiling and real world data, particularly as AI tools transform how we diagnose and treat cancer," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "The data from our internal and collaborative studies show that we are entering a new era of precision oncology, where every data point can support smarter, more personalized decision-making."

"Caris’ strong presence at ASCO (Free ASCO Whitepaper) demonstrates our ongoing commitment to revolutionizing healthcare and improving patient outcomes," said James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance. "Caris’ comprehensive clinicogenomic database helps enable novel insights into cancer and, together with our network of Caris POA researchers, is truly making an impact on patients’ diagnosis, prognosis, care plans and responses to treatment."

Oral presentation:

CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment. (Abstract 4520)
May 31, 2:15 – 2:21 PM CDT: Arie Crown Theater

Poster presentations:

Assessment of age in the clinical risk stratification of patients with IDH-mutant gliomas.
Abstract: 2058 Poster Board: 104 May 31, 9:00 AM CDT: Hall A

Comparing ERK signaling and tumor microenvironment in BRAF-altered gliomas.
Abstract: 2063 Poster Board: 109 May 31, 9:00 AM CDT: Hall A

Association of MGMT status with survival in low and high-grade IDH-mutant astrocytomas.
Abstract: 2065 Poster Board: 111 May 31, 9:00 AM CDT: Hall A

Prognostic impact of DDR mutations (mt) in IDH mutant high-grade gliomas (HGG).
Abstract: 2066 Poster Board: 112 May 31, 9:00 AM CDT: Hall A

Immune checkpoint inhibition in EBV-associated gastric cancer: A multi-center international retrospective analysis.
Abstract: 4043 Poster Board: 333 May 31, 9:00 AM CDT: Hall A

Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter?
Abstract: 4124 Poster Board: 414 May 31, 9:00 AM CDT: Hall A

The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC).
Abstract: 4166 Poster Board: 456 May 31, 9:00 AM CDT: Hall A

Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).
Abstract: 4176 Poster Board: 466 May 31, 9:00 AM CDT: Hall A

Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, comprehensive genomic study of desmoids and CTNNB1/APC mutated soft tissue tumors.
Abstract: 11547 Poster Board: 30 May 31, 9:00 AM CDT: Hall A

Unveiling drivers of MHC repression and therapeutic strategies to counter immune evasion in small cell lung cancer.
Abstract: 8091 Poster Board: 212 May 31, 1:30 PM CDT: Hall A

Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC).
Abstract: 8538 Poster Board: 18 May 31, 1:30 PM CDT: Hall A

PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone-receptor-positive breast cancer.
Abstract: 1556 Poster Board: 322 June 1, 9:00 AM CDT: Hall A

Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data.
Abstract: 569 Poster Board: 162 June 2, 9:00 AM CDT: Hall A

MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.
Abstract: 570 Poster Board: 163 June 2, 9:00 AM CDT: Hall A

Evaluation of tumor immune microenvironment in Hispanic and African American breast cancer.
Abstract: 1051 Poster Board: 30 June 2, 9:00 AM CDT: Hall A

Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC).
Abstract: 1076 Poster Board: 55 June 2, 9:00 AM CDT: Hall A

Steroid receptor expression and overall survival in breast cancer patients with ER+ bone metastasis: A retrospective review.
Abstract: 1077 Poster Board: 56 June 2, 9:00 AM CDT: Hall A

Multiomic Profiling of LRRC15 in Triple Negative Breast Cancer (TNBC).
Abstract: 1098 Poster Board: 77 June 2, 9:00 AM CDT: Hall A

Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) benefit in triple negative breast cancer (TNBC).
Abstract: 1106 Poster Board: 85 June 2, 9:00 AM CDT: Hall A

Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
Abstract: 1107 Poster Board: 86 June 2, 9:00 AM CDT: Hall A

Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC).
Abstract: 1114 Poster Board: 93 June 2, 9:00 AM CDT: Hall A

HIF family transcription factor expression in a cohort of 4362 patients with renal cell carcinoma (RCC).
Abstract: 4543 Poster Board: 343 June 2, 9:00 AM CDT: Hall A

Real-world analysis of 2IR immune response score in histologic subtype urothelial carcinoma (hsUC).
Abstract: 4568 Poster Board: 368 June 2, 9:00 AM CDT: Hall A

Prevalence of histology-agnostic biomarkers in pure squamous cell carcinomas of the genitourinary tract.
Abstract: 4609 Poster Board: 409 June 2, 9:00 AM CDT: Hall A

Comprehensive genomic profiling of Black and non-Hispanic White (NHW) men with prostate cancer (PCa).
Abstract: 5022 Poster Board: 221 June 2, 9:00 AM CDT: Hall A

Effect of HLA class I expression on the tumor immune microenvironment and prognosis in prostate cancer.
Abstract: 5044 Poster Board: 243 June 2, 9:00 AM CDT: Hall A

Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC).
Abstract: 5050 Poster Board: 249 June 2, 9:00 AM CDT: Hall A

Prognostic relevance of Aurora kinase A (AURKA) expression in prostate cancer (PCa).
Abstract: 5061 Poster Board: 260 June 2, 9:00 AM CDT: Hall A

Molecular characterization of STEAP1 and -2 in advanced prostate cancer.
Abstract: 5072 Poster Board: 271 June 2, 9:00 AM CDT: Hall A

Characterization and impact of B7-H3 (CD276) expression across disease states and racial groups in prostate cancer.
Abstract: 5073 Poster Board: 272 June 2, 9:00 AM CDT: Hall A

Survival association of PIK3CA in HPV-driven head and neck squamous cell carcinoma (HNSCC).
Abstract: 6056 Poster Board: 464 June 2, 9:00 AM CDT: Hall A

Comparative transcriptomic analysis to identify similarities and therapeutic vulnerabilities in olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC).
Abstract: 6095 Poster Board: 503 June 2, 9:00 AM CDT: Hall A

BRAF-V600E papillary thyroid cancer: Updated analysis of real-world patient data.
Abstract: 6099 Poster Board: 507 June 2, 9:00 AM CDT: Hall A

Clinical significance of the CGRP pathway gene expression in advanced solid tumors: A sub-analysis of MONSTAR-SCREEN-2.
Abstract: 2629 Poster Board: 276 June 2, 1:30 PM CDT: Hall A

Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer.
Abstract: 2633 Poster Board: 280 June 2, 1:30 PM CDT: Hall A

Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model.
Abstract: 3135 Poster Board: 450 June 2, 1:30 PM CDT: Hall A

Poster and abstract summaries highlighting this research will be available onsite at Caris’ booth #23093. The full abstracts will be available on the Caris website following the presentation.

The Caris POA, a community of investigators, includes 97 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.

On May 22, 2025 Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, reported that management will present at the following investor conferences (Press release, Enliven Therapeutics, MAY 22, 2025, View Source [SID1234653338]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 6th Annual Oncology Innovation Summit: Insights from ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper)
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 1:00 p.m. ET

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET

Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, June 10, 2025
Time: 4:00 p.m. ET

The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at View Source Each webcast will be archived for a period of 90 days following the conclusion of the live event.